[Federal Register: September 10, 2007 (Volume 72, Number 174)]
[Notices]               
[Page 51664]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10se07-77]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on July 19, 2007, CIMA Labs, 
Inc., 7325 Aspen Lane, Brooklyn Park, Minnesota 55428, made application 
by letter to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Nabilone (7379), a basic class of controlled 
substance listed in schedule II.
    The company plans to import the basic class of controlled substance 
for clinical trials and research.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC 20537, or any being sent via express mail should be sent 
to Drug Enforcement Administration, Office of Diversion Control, 
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than October 10, 
2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in schedule I or II are, and will continue to be required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

    Dated: August 28, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-17766 Filed 9-7-07; 8:45 am]

BILLING CODE 4410-09-P